Results 1 to 10 of about 133,829 (277)

Inhibiting NHEJ: In-Silico Approach to Stratifying DNA-PK Inhibitors, Predicting Radio-Halogenation Potential of DNA-PK Inhibitors, and Assessing AlphaFold2 Prediction Accuracy. [PDF]

Bioengineering (Basel)
Niculae DA, Crișu FV, Stoian S, Ion GND, Drăgănescu D.   +4 more
europepmc   +1 more source

Performance of Meta's Universal Model for Atoms across the Conformational and Configurational Space of Diverse Transition-Metal Catalysts. [PDF]

J Phys Chem A
Kalikadien AV, Pidko EA.
europepmc   +1 more source

Estrogens and the osteoprotegerin/RANK-ligand system

, 2018
Hofbauer, L. C., Viereck, Volker
openaire   +1 more source

Molecular Dynamics Workflows to Compute Large-Scale Sets of Absolute Binding Free Energies Aiding Drug Candidate and Binding Pose Selection. [PDF]

J Chem Theory Comput
Wingbermühle S, Biswas AD, Bonanni D, Shugaeva T, Gadioli D, Beránek J, Frumenzio G, Querciagrossa L, Piserchia A, Accordi G, Lunghini F, Talarico C, Emerson A, Martinovič J, Rosario Beccari A, Palermo G, Lindahl E.   +16 more
europepmc   +1 more source

PrimaDORAC: An improved Web Interface for Rapid GAFF2 Parameter Assignment with ABCG2 Charge Models for Drug Design Applications. [PDF]

J Comput Chem
Procacci P.
europepmc   +1 more source

RANK Ligand: Effects of Inhibition

Current Oncology Reports, 2010
Receptor activator of nuclear factor kappa-light-chain-enhancer of activated B-cells (RANK) and its ligand (RANKL) belong to the tumor necrosis factor (TNF) superfamily. RANK mRNA is expressed widely in bone and bone marrow. It has a significant role in stimulating osteoclast differentiation and maturation, and also in preventing apoptosis.
Saby George, Brenner Andrew, Bukowski Ronald M   +2 more
exaly   +3 more sources

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Clinical Therapeutics, 2012
Postmenopausal osteoporosis results from bone loss and decreased bone strength mediated by an increased rate of bone remodeling secondary to reduced estrogen levels. Remodeling cycles are initiated by osteoclasts, the formation, function, and survival of which depend on RANK ligand (RANKL).
David Dempster
exaly   +3 more sources

RANK ligand inhibition with denosumab for the management of osteoporosis

Expert Opinion on Biological Therapy, 2006
Receptor activator of nuclear factor-kappaB ligand (RANKL) is a cytokine member of the tumour necrosis factor family that is the principal final mediator of osteoclastic bone resorption. It plays a major role in the pathogenesis of postmenopausal osteoporosis, as well bone loss associated with rheumatoid arthritis, metastatic cancer, multiple myeloma ...
E Michael Lewiecki
exaly   +3 more sources

The affinity of human RANK binding to its ligand RANKL

Archives of Biochemistry and Biophysics, 2009
Receptor activator of nuclear factor-kappa B (RANK) and its ligand, RANKL play critical roles in bone re-modeling, immune function, vascular disease and mammary gland development. To study the interaction of RANK and RANKL, we have expressed both extracellular domain of RANK and ectodomain of RANKL using Escherichia coli expression system.
Changzhen Liu, Jingshan Ren, Zhenggang Bi   +2 more
exaly   +3 more sources

RANK ligand

The International Journal of Biochemistry & Cell Biology, 2007
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding
J M, Blair, Y, Zheng, C R, Dunstan
openaire   +2 more sources